On July 9, the two entities signed a memorandum of understanding at Seoul National University Hospital,, pledging to combine an AI-driven platform with clinical data to integrate an AI-driven platform with clinical data to establish a precision drug discovery framework.
Under the agreement, Seoul National University Hospital will contribute prospective clinical trial support, patient datasets, and research design expertise. OncoCross will leverage its proprietary AI platform, RAPTOR AI, to identify therapeutic targets and generate drug candidates for intractable conditions such as cancer and rare diseases.

RAPTOR AI examines patient gene expression profiles and biomolecular data to precisely pinpoint disease mechanisms and expedite the selection of promising drug candidates. The technology holds significant potential for addressing cancers and rare diseases with limited treatment options.
Yi-rang Kim, CEO of OncoCross, described the partnership as “a pivotal step for AI-driven drug discovery grounded in clinical evidence.” She added, “Our focus will be on developing tailored therapies for diseases with few treatment alternatives.”
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr